Search

Your search keyword '"Sola, Patrizia"' showing total 540 results

Search Constraints

Start Over You searched for: Author "Sola, Patrizia" Remove constraint Author: "Sola, Patrizia"
540 results on '"Sola, Patrizia"'

Search Results

1. Longitudinal modeling of MS patient trajectories improves predictions of disability progression

2. Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic

3. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

4. PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study

5. Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry

6. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression

8. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study

9. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study

10. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study

11. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

13. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study

14. Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years

15. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy

16. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

17. Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a

18. Disability accrual in primary and secondary progressive multiple sclerosis

19. Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS

20. Effectiveness of multiple disease- modifying therapies in relapsing- remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.

23. Comparative effectiveness in multiple sclerosis: A methodological comparison

24. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

25. Disability accrual in primary and secondary progressive multiple sclerosis

27. Definitive childlessness in women with multiple sclerosis: a multicenter study

28. A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band

30. Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis

31. Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register

32. Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS

33. Confirmed disability progression as a marker of permanent disability in multiple sclerosis

34. Comparing the natural history of pediatric multiple sclerosis with onset before or after pubertal age (P1-5.005)

35. Trajectories of disability and relapse-rate in naïve patients on oral drugs: results from the Italian Multiple Sclerosis Register (P17-4.003)

37. sj-docx-1-msj-10.1177_13524585221084577 – Supplemental material for Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS

38. Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study

39. Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS

40. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response

41. Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis

42. Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.

43. Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180]

44. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study

45. Comparing Natural History of Early and Late Onset Pediatric Multiple Sclerosis

46. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years

48. Progression independent of relapse activity in early multiple sclerosis patients

50. Comparative effectiveness of early intensive or escalation treatment strategies on long term disability trajectories in relapsing multiple sclerosis patients

Catalog

Books, media, physical & digital resources